The 2026 dyslipidemia guidelines made news this year for a major first: recommending that every adult get a one-time blood test for lipoprotein(a), or Lp(a)—pronounced "LP little a." In clinical cardiology practice, I often hear patients confuse Lp(a) with apolipoprotein B (ApoB). While both help spot cardiovascular risks that standard cholesterol panels miss, they perform two very different jobs. ApoB is a headcount of all the plaque-causing particles in your bloodstream, while Lp(a) is a specific, inherited particle that carries its own independent risk.

Here is how to make sense of both numbers, why they matter, and what to ask your doctor at your next visit.

Lipoprotein(a): The One-Time Genetic Test

Lp(a) is essentially an LDL particle with an extra protein wrapped around it. Unlike standard LDL cholesterol, your Lp(a) level is 80% to 90% determined by your genes. Diet, exercise, and weight loss barely move it, and standard cholesterol-lowering medications like statins do not lower it either. Because your level remains relatively stable throughout adulthood, a single blood test in your lifetime is generally all you need.

Under the 2026 guidelines, an Lp(a) level above 125 nmol/L raises cardiovascular risk, and anything above 250 nmol/L is considered high. (If your commercial lab reports in milligrams per deciliter, levels above 30 to 50 mg/dL generally indicate elevated risk.)

There are currently no FDA-approved medications specifically designed to lower Lp(a), though several targeted therapies, including pelacarsen and olpasiran, are in late-stage clinical trials. For now, knowing your Lp(a) number tells your physician how aggressively to manage the risk factors we can control: lowering LDL cholesterol and blood pressure, optimizing blood sugar, and quitting smoking. Because Lp(a) runs silently in families, an elevated result is also a signal that first-degree relatives (parents, siblings, and children) should get tested.

ApoB: The Precision Treatment Tracker

While Lp(a) is a universal screening test for every adult, ApoB is a targeted monitoring tool.

Standard lipid panels measure LDL cholesterol (LDL-C), which calculates the total weight of cholesterol packed inside your particles. But cardiovascular events are driven primarily by the number of plaque-causing particles entering the artery wall, not just the amount of cholesterol carried inside each one. Two people can share the same LDL-C level of 100 mg/dL, yet one can have a significantly higher particle concentration in circulation than the other.

ApoB solves this problem. Every plaque-causing particle—including LDL, VLDL, IDL, and Lp(a)—carries exactly one ApoB protein on its surface. Measuring ApoB gives a direct headcount of every atherogenic particle in your blood (excluding "good" HDL cholesterol, which uses a different structural protein).

I order ApoB regularly. It is especially useful for patients already taking cholesterol medications who have existing heart disease, type 2 diabetes, high triglycerides, or an LDL level that is not dropping as expected. It reveals whether treatment has actually cleared plaque-causing particles from circulation or if hidden residual risk remains.

What This Means for Your Next Checkup

These two tests complement each other to give a complete picture of cardiovascular health:

Neither marker replaces daily healthy habits, but together they remove the blind spots of standard lipid testing.

Reference Source: HCPLive — Expert Insights: Lp(a) and ApoB in the 2026 Dyslipidemia Guidelines

Journal Article: JACC — Seeing the Whole Picture: Apolipoprotein B and Lipoprotein(a) in the 2026 Dyslipidemia Guideline (subscription required)